Business Wire

CA-NUCLEIX

29.10.2020 13:02:08 CET | Business Wire | Press release

Share
Nucleix’s Lung EpiCheck® Liquid Biopsy Test Detects 85% of Early Stage Lung Cancers in High-Risk Smokers, Study Published in European Respiratory Journal

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced a publication showing its Lung EpiCheck® test detected 85% of early stage lung cancers among individuals at high risk for developing the disease based on their history of smoking. The study, entitled “Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals,” was published online today ahead of print in the European Respiratory Journal (ERJ).

Lung EpiCheck analyzed 728 different samples in the study, including 311 from individuals with varying stages of lung cancer and 417 matched controls. By adjusting measurement of six methylation markers found in blood, the test was tailored to meet the needs of specific patient populations: increased sensitivity for high-risk populations, or increased specificity for low-risk populations. When focused on increased sensitivity for a high-risk population of past and current smokers, Lung EpiCheck demonstrated an overall sensitivity of 87% detection of lung cancer across all stages, 85% detection of Stages I-IIIA non-small cell lung cancer (NSCLC) and 78% detection of Stage I NSCLC, each with a specificity of 64%. The test also detected 100% of small cell lung cancer, a rapidly growing and deadly cancer that is typically challenging to detect. When focused on increased specificity for a low-risk population, Lung EpiCheck demonstrated overall specificity of 91% and sensitivity of 74%. Combining Lung EpiCheck with established risk factors improved the AUC, the ability to distinguish between patients with and without disease, from 88% to 94%.

“In the United States, very few high-risk individuals follow the recommended screening guidelines of annual, low-dose CT scans. Offering a highly sensitive test to those who decline to undergo the recommended scan gives them a better chance for early detection, while a false positive would simply result in proceeding to the current standard of care,” said Chris Hibberd, chief executive officer of Nucleix. “We are taking steps to further advance Lung EpiCheck as a low-cost blood test to encourage more patients to comply with recommended screening.”

Lung cancer is the deadliest cancer, with 1.76 million deaths worldwide in 2018.1 Survival hinges on early detection, with 5-year survival rates nearly 10 times greater for Stage I cancer than Stage IV cancer.2 The U.S. Preventive Services Task Force recommends annual screening with low-dose computed tomography (also called a low-dose CT scan, or LDCT) for current and past smokers at the highest risk of developing lung cancer – specifically, those individuals age 55-80 who have smoked an average of one pack of cigarettes a day for more than 30 years and currently smoke, or who quit, within the past 15 years.3 Even though there is no cost to these individuals to receive a LDCT scan, and it has been shown to improve survival,4 only 7%5 to 14%6 of those eligible in the United States follow this guideline due to a combination of inconvenience, missing infrastructure and fear of radiation exposure.

“Lung cancer is most often diagnosed at late stages when chances of cure are limited,” said Prof. Mina Gaga, Director and Head, 7th Respiratory Medicine Department, Athens Chest Hospital and the principal investigator of the study. “Tests for early diagnosis are urgently needed and the Lung EpiCheck data published in the ERJ show important promise for the implementation of lung cancer screening.”

Nucleix is continuing to optimize the Lung EpiCheck test and is advancing development of next-generation versions, with a goal of making a test available within 1 to 2 years.

About Lung EpiCheck®

Lung EpiCheck is designed to provide a simple blood test to detect lung cancer at its earliest stages. The test utilizes PCR-based technology for a low-cost analysis of subtle, disease-specific changes in DNA methylation markers. Lung EpiCheck is being developed for potential use in individuals with a history of smoking who are at high-risk of developing lung cancer, and do not comply with the guidelines for annual screening with LDCT scans. The test is not yet commercially available.

About Nucleix

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck testing kit, marketed in Europe for bladder cancer recurrence. The Company is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases. For more information, please visit: https://www.nucleix.com .


1 GLOBOCAN2018 Global Cancer Observatory http://gco.iarc.fr .
2 Lung cancer Stat Facts: Lung and Bronchus Cancer. https://seer.cancer.gov/statfacts/html/lungb.html entered October 2020.
3 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
4 NEJM Research team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395-409.
5 LCSR Available Facility Reports. (n.d.). Retrieved October 28, 2020, from https://nrdrsupport.acr.org/support/solutions/articles/11000039783-lcsr-available-reports
6 Zahnd WE, Eberth JM. Lung cancer screening utilization: A behavioral risk factor surveillance system analysis. Am J Prev Med. 2019;57:250-255. doi: 10.1016/j.amepre.2019.03.015.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 13:00:00 CET | Press release

Since 2018, the competition’s 52 finalists have raised more than €700 million The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achie

New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 13:00:00 CET | Press release

Report urges tourism leaders to focus on high-value trips, not just high-spending visitors, and measure benefits retained by local communities Nearly 150 million more households could afford international leisure travel by 2030, including almost 110 million in Asia Pacific 59% of surveyed AI users turn to AI for travel information, but only 12% of consumers in a separate survey trust it to make decisions independently 43% of travelers surveyed across 35 markets planned to avoid overcrowded destinations in 2026 Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the p

Rockwell Automation Signs Definitive Agreement to Acquire AGILOX18.11.2026 13:00:00 CET | Press release

This acquisition accelerates our physical AI strategy and creates a comprehensive autonomous mobile robot portfolio Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has signed a definitive agreement to acquire Austria-based AGILOX, a maker of high-end autonomous mobile robots (AMRs) that are driven by self-developed artificial intelligence and swarm networking technology. Together, AGILOX’s proven forklift AMR portfolio and OTTO by Rockwell Automation’s flatbed AMR platform will create a comprehensive autonomous material movement offering, elevating AGILOX from a best-in-class point solution to a cornerstone of a world-class comprehensive production logistics capability. The acquisition will combine OTTO's strong presence in North America with AGILOX's established footprint across Europe. AGILOX will gain access to Rockwell's deep customer relationships in strategic verticals like consum

Ant International Pioneers PayNow Deep-Linking for E-Commerce, Explores Government Services Use Case Under MAS’ PayNow Gen2 Initiative18.11.2026 12:40:00 CET | Press release

Ant International’s Antom is the first to implement PayNow deep-link for e-commerce, via Lazada, with ~9% uplift in payment success rate.2C2P by Antom is collaborating with the Government Technology Agency of Singapore (GovTech Singapore) to explore PayNow deep-linking capabilities through GovWallet.Ant International will further explore supporting PayNow Gen2, including through its global wallet gateway Alipay+ expanding SGQR+ interoperability, and introducing AI-powered digital services for consumers and merchants. Ant International is the first partner under the Monetary Authority of Singapore (MAS)’s PayNow Generation 2.0 launch to introduce live use cases for deep-linking for e-commerce and digital government services. The launch is enabled by Antom, its global merchant payment and digitisation services provider, and Antom’s Southeast Asia subsidiary, 2C2P by Antom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202611183

IFF Opens Its First Forest Lab in Brazil's Atlantic Forest to Advance Fragrance and Beauty Innovation18.11.2026 12:30:00 CET | Press release

New lab at Legado das Águas, Brazil’s largest private Atlantic Forest reserve, connects biodiversity with scientific discovery and innovation in perfumery and beauty. IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today opened its first Forest Lab at Legado das Águas, Brazil's largest private Atlantic Forest reserve. The lab is the next step in the bioprospecting partnership IFF announced in August 2025 with Reservas Votorantim (rV), the green economy division of Brazilian investment firm Votorantim SA, which manages the reserve. Spanning 31,000 hectares and home to nearly 1,000 plant species, Legado das Águas now hosts biodiversity research, scent discovery, perfumery and beauty innovation in one place, while supporting rV's conservation work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117495933/en/ A scientist in the new IFF Brazil Forest Lab at Legado das Águas, the country’s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye